Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 008064206 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 2
|
8.3% |
8/14/2026
Event 6/30/2026
|
|
| Venrock Healthcare Capital Partners III, L.P. | 8.3% | ||
| VHCP Co-Investment Holdings III, LLC | 8.3% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 8.3% | ||
| VHCP Management III, LLC | 8.3% | ||
| VHCP Management EG, LLC | 8.3% | ||
| Nimish Shah | 8.3% | ||
| Bong Y. Koh | 8.3% | ||
|
Bellevue Group AG
13G/A
Amendment 1
|
5.0% |
8/14/2026
Event 6/30/2026
|
|
| Bellevue Group AG | 5.0% | ||
| Bellevue Asset Management AG | 5.0% | ||
|
Paradigm Biocapital Advisors LP
13G
|
5.1% |
7/17/2026
Event 7/10/2026
|
|
| Paradigm BioCapital Advisors LP | 5.1% | ||
| Paradigm BioCapital Advisors GP LLC | 5.1% | ||
| Senai Asefaw, M.D. | 5.1% | ||
| Paradigm BioCapital International Fund Ltd. | 4.5% | ||
| Janus Henderson Group Ltd. 13G/A Amendment 2 | 10.6% |
7/8/2026
Event 6/30/2026
|
|
|
Fairmount Funds Management LLC
13D/A
Amendment 2
|
20.0% |
6/9/2026
Event 6/5/2026
|
|
| Fairmount Funds Management LLC | 20.0% | ||
| Fairmount Healthcare Fund II L.P. | 16.2% | ||
| Fairmount Healthcare Co-Invest IV L.P. | 4.4% | ||
| Peter Evan Harwin | 20.0% | ||
| Tomas Kiselak | 20.0% | ||
| Janus Henderson Group PLC 13G/A Amendment 1 | 6.3% |
5/15/2026
Event 3/31/2026
|
|
| BlackRock, Inc. 13G/A Amendment 2 | 4.7% |
4/27/2026
Event 3/31/2026
|
|
|
Sofinnova Venture Partners X, L.P.
13D/A
Amendment 3
|
0.3% |
3/5/2026
Event 4/28/2025
|
|
| Sofinnova Venture Partners X, L.P. ("SVP X") | 0.3% | ||
| Sofinnova Management X, L.P. ("SM X LP") | 0.3% | ||
| Sofinnova Management X-A, L.L.C. ("SM X LLC") | 0.3% | ||
| Dr. James I. Healy ("Healy") | 0.3% | ||
| Dr. Maha Katabi ("Katabi") | 0.3% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 1
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||
| VHCP Management III, LLC | 9.9% | ||
| VHCP Management EG, LLC | 9.9% | ||
| Nimish Shah | 9.9% | ||
| Bong Y. Koh | 9.9% | ||
| Janus Henderson Group PLC 13G | 6.2% |
2/17/2026
Event 12/31/2025
|
|
|
Bellevue Group AG
13G
|
6.8% |
2/17/2026
Event 12/16/2025
|
|
| Bellevue Group AG | 6.8% | ||
| Bellevue Asset Management AG | 6.8% | ||
|
Deep Track Capital, LP
13G/A
Amendment 2
|
0% |
2/13/2026
Event 12/31/2025
|
|
| Deep Track Capital, LP | 0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | ||
| David Kroin | 0% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 4.2% |
1/30/2026
Event 12/31/2025
|
|
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 2
|
4.2% |
11/14/2025
Event 9/30/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 4.2% | ||
| FHMLSP, L.P. | 4.2% | ||
| FHMLSP, L.L.C. | 4.2% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0.1% | ||
| FHMLS XI, L.P. | 0.1% | ||
| FHMLS XI, L.L.C. | 0.1% | ||
| James N. Topper | 0% | ||
| Patrick J. Heron | 0% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
7.0% |
11/14/2025
Event 9/30/2025
|
|
| Deep Track Capital, LP | 7.0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 7.0% | ||
| David Kroin | 7.0% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 6.6% |
10/17/2025
Event 9/30/2025
|
|
|
RA Capital Management, L.P.
13G
|
7.0% |
10/16/2025
Event 10/8/2025
|
|
| RA Capital Management, L.P. | 7.0% | ||
| Peter Kolchinsky | 7.0% | ||
| Rajeev Shah | 7.0% | ||
| RA Capital Healthcare Fund, L.P. | 7.0% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 1
|
20.0% |
10/8/2025
Event 10/6/2025
|
|
| Fairmount Funds Management LLC | 20.0% | ||
| Fairmount Healthcare Fund II L.P. | 14.9% | ||
| Fairmount Healthcare Co-Invest IV L.P. | 5.8% | ||
| Peter Evan Harwin | 20.0% | ||
| Tomas Kiselak | 20.0% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
4.2% |
8/14/2025
Event 6/30/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 4.2% | ||
| FHMLSP, L.P. | 4.2% | ||
| FHMLSP, L.L.C. | 4.2% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.2% | ||
| FHMLSP Overage, L.P. | 1.2% | ||
| FHMLSP Overage, L.L.C. | 1.2% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0.1% | ||
| FHMLS XI, L.P. | 0.1% | ||
| FHMLS XI, L.L.C. | 0.1% | ||
| James N. Topper | 0% | ||
| Patrick J. Heron | 0% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
| Vanguard Group Inc 13G | 5.6% |
7/29/2025
Event 6/30/2025
|
|
| BlackRock, Inc. 13G | 5.3% |
7/17/2025
Event 6/30/2025
|
|
|
Deep Track Capital, LP
13G
|
8.6% |
6/20/2025
Event 4/28/2025
|
|
| Deep Track Capital, LP | 8.6% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 8.6% | ||
| David Kroin | 8.6% | ||
|
FMR LLC
13G
|
14.7% |
6/6/2025
Event 5/30/2025
|
|
| FMR LLC | 14.7% | ||
| Abigail P. Johnson | 14.7% | ||
|
TCG Crossover GP I, LLC
13G/A
Amendment 1
|
0.2% |
5/15/2025
Event 4/28/2025
|
|
| TCG Crossover GP I, LLC | 0.2% | ||
| TCG Crossover Fund I, L.P. | 0.2% | ||
| Chen Yu | 0.2% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G
|
9.9% |
5/5/2025
Event 4/28/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | ||
| VHCP Co-Investment Holdings III, LLC | 9.9% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | ||
| VHCP Management III, LLC | 9.9% | ||
| VHCP Management EG, LLC | 9.9% | ||
| Nimish Shah | 9.9% | ||
| Bong Y Koh | 9.9% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
5.5% |
5/5/2025
Event 4/28/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 4.2% | ||
| FHMLSP, L.P. | 4.2% | ||
| FHMLSP, L.L.C. | 4.2% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.2% | ||
| FHMLSP Overage, L.P. | 1.2% | ||
| FHMLSP Overage, L.L.C. | 1.2% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0.1% | ||
| FHMLS XI, L.P. | 0.1% | ||
| FHMLS XI, L.L.C. | 0.1% | ||
| James N. Topper | 5.5% | ||
| Patrick J. Heron | 5.5% | ||
| Albert Cha | 5.4% | ||
| James Brush | 5.4% | ||
| Daniel Estes | 0.1% | ||
|
Fairmount Funds Management LLC
13D
|
20.0% |
5/1/2025
Event 4/28/2025
|
|
| Fairmount Funds Management LLC | 20.0% | ||
| Fairmount Healthcare Fund II L.P. | 12.7% | ||
| Fairmount Healthcare Co-Invest IV L.P. | 8.2% | ||
| Peter Evan Harwin | 20.0% | ||
| Tomas Kiselak | 20.0% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 4
|
4.1% |
4/30/2025
Event 4/28/2025
|
|
| RA Capital Management, L.P. | 4.1% | ||
| Peter Kolchinsky | 4.1% | ||
| Rajeev Shah | 4.1% | ||
| RA Capital Healthcare Fund, L.P. | 4.0% | ||
|
Atlas Venture Fund XII, L.P.
13D/A
Amendment 4
|
0.2% |
4/30/2025
Event 4/28/2025
|
|
| Atlas Venture Fund XII, L.P. | 0.2% | ||
| Atlas Venture Associates XII, L.P. | 0.2% | ||
| Atlas Venture Associates XII, LLC | 0.2% |